Critical appraisal of denosumab in the treatment and prevention of postmenopausal osteoporosis and bone loss in patients undergoing hormone ablation
David L Kendler1, Kenneth Shawn Davison21Prohealth Clinical Research, University of British Columbia, Vancouver, British Columbia, Canada; 2Department of Medicine, Division of Immunology and Rheumatology, Laval University, Quebec, CanadaAbstract: Antiresorptive therapies are the mainstay for treatin...
Main Authors: | David L Kendler, Kenneth Shawn Davison |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2010-09-01
|
Series: | Orthopedic Research and Reviews |
Online Access: | http://www.dovepress.com/critical-appraisal-of-denosumab-in-the-treatment-and-prevention-of-pos-a5380 |
Similar Items
-
Treatment-Induced Bone Loss and Fractures in Cancer Patients Undergoing Hormone Ablation Therapy: Efficacy and Safety of Denosumab
by: Allan Lipton, et al.
Published: (2012-08-01) -
Treatment-Induced Bone Loss and Fractures in Cancer Patients Undergoing Hormone Ablation Therapy: Efficacy and Safety of Denosumab
by: Allan Lipton, et al.
Published: (2012-01-01) -
Safety and efficacy of denosumab in postmenopausal somen with osteoporosis
by: Dilsad Sindel, et al.
Published: (2020-10-01) -
Denosumab: an investigational drug for the management of postmenopausal osteoporosis
by: E Michael Lewiecki
Published: (2008-08-01) -
Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
by: Yong-Ki Min
Published: (2015-03-01)